Țară: Israel
Limbă: ebraică
Sursă: Ministry of Health
PALIVIZUMAB 50 MG
ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL
J06BB16
POWDER FOR SOLUTION FOR INJECTION
I.M
ABBVIE S.R.L., ITALY
PALIVIZUMAB
Is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV). Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.
2010-07-01